A new breakthrough blood test that can reportedly able to spot more than 50 different types of cancer early on has been hailed as a “ground-breaking advancement” that could have tremendous human and economic benefits. The test, known as Galleri, was created by California-based biotechnology and pharmaceutical company Grail, which is also in partnership with the Mayo Clinic. In a large-scale, clinical validation sub-study of circulating cell-free genome atlas (CCGA), the Galleri test detected more than 50 cancer types across all stages through a simple blood draw. Galleri works by looking for signals in the bloodstream that may be associated with cancer at a blood draw. If such a cancer signal is detected, Galleri results can point to where in the body the cancer is coming from. The results of the test will be available after two weeks. The Galleri test uses next-generation sequencing (NGS) and machine-learning algorithms to analyze methylation patterns of cell-free DNA (cfDNA) in the bloodstream, which can carry …